Quintrio
Home

PHARMACEUTICAL PREPARATIONS

First Tracks Biotherapeutics, Inc. Ordinary Shares

TRAX

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

Last trade $43.86
Day change -$2.70 (-5.80%)
Day range $43.67 – $47.07
Volume 306,336
Market cap $1.96B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.96B
Price / earnings
—
Price / book
12.96×
Price / sales
—
EV / sales
—
EV / EBITDA
-10.9×

Profitability

Earnings per share
-$3.74
Return on assets
-92.15%
Return on equity
-104.01%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
9.16×
Quick ratio
9.16×
Cash ratio
8.6×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$112.28M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TRAX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026
Revenue$0$0
Cost of revenue$0$0
Gross profit$0$0
Selling, general and administrative$9M$9.29M
Research and development$23.85M$25.64M
Total operating expenses$32.84M$34.94M
Operating income-$32.84M-$34.94M
Interest expense$0$0
Income before taxes-$31.36M-$33.37M
Income taxes$0$0
Net income-$31.36M-$33.37M
Net income attributable to common shareholders-$31.36M-$33.37M
EBITDA-$32.75M-$34.83M
Basic earnings per share-$0.88-$0.95
Diluted earnings per share-$0.88-$0.95

Recent news

Company coverage with links to the original publishers.

Publication times in UTC

No recent company news found.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.